Envveno Medical Corp Stock Alpha and Beta Analysis
| NVNO Stock | USD 2.91 0.12 4.30% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as enVVeno Medical Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in EnVVeno Medical over a specified time horizon. Remember, high EnVVeno Medical's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to EnVVeno Medical's market risk premium analysis include:
Beta 1.29 | Alpha 0.15 | Risk 4.65 | Sharpe Ratio 0.0287 | Expected Return 0.13 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
EnVVeno |
EnVVeno Medical Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. EnVVeno Medical market risk premium is the additional return an investor will receive from holding EnVVeno Medical long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in EnVVeno Medical. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate EnVVeno Medical's performance over market.| α | 0.15 | β | 1.29 |
EnVVeno Medical expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of EnVVeno Medical's Buy-and-hold return. Our buy-and-hold chart shows how EnVVeno Medical performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.EnVVeno Medical Market Price Analysis
Market price analysis indicators help investors to evaluate how EnVVeno Medical stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading EnVVeno Medical shares will generate the highest return on investment. By understating and applying EnVVeno Medical stock market price indicators, traders can identify EnVVeno Medical position entry and exit signals to maximize returns.
EnVVeno Medical Return and Market Media
The median price of EnVVeno Medical for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 3.15 with a coefficient of variation of 9.0. The daily time series for the period is distributed with a sample standard deviation of 0.28, arithmetic mean of 3.16, and mean deviation of 0.23. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Jenusaitis Matthew of 19752 shares of EnVVeno Medical at 2.57 subject to Rule 16b-3 | 12/18/2024 |
2 | Acquisition by Robert Berman of 12000 shares of EnVVeno Medical at 2.55 subject to Rule 16b-3 | 12/19/2024 |
3 | Acquisition by Shrivastava Sanjay of 5673 shares of EnVVeno Medical subject to Rule 16b-3 | 12/20/2024 |
4 | Insider Buying Matthew Jenusaitis Acquires 9,620 Shares of enVVeno Medical Corp | 12/23/2024 |
5 | Acquisition by Shrivastava Sanjay of 5400 shares of EnVVeno Medical at 2.9 subject to Rule 16b-3 | 12/24/2024 |
6 | Insider Buying Sanjay Shrivastava Acquires Shares in enVVeno Medical Corp | 12/27/2024 |
7 | Acquisition by Gray Robert of 3500 shares of EnVVeno Medical at 2.94 subject to Rule 16b-3 | 12/31/2024 |
8 | Insider Buying Francis Duhay Acquires Shares of enVVeno Medical Corp - GuruFocus.com | 01/03/2025 |
9 | Companies Like enVVeno Medical Are In A Position To Invest In Growth | 01/17/2025 |
10 | Interim Two-Year Follow-Up Data from the VenoValve U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting | 02/07/2025 |
11 | One-Year Data from the VenoValve U.S. Pivotal Trial Highlighting Impact on Patients Quality of Life to be Presented Today at the 37th Annual Meeting of the Amer... | 02/19/2025 |
12 | Acquisition by Duhay Francis of 81433 shares of EnVVeno Medical at 3.07 subject to Rule 16b-3 | 02/27/2025 |
13 | Disposition of 125925 shares by Hamed Alavi of EnVVeno Medical at 6.7 subject to Rule 16b-3 | 03/10/2025 |
About EnVVeno Medical Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including EnVVeno or other stocks. Alpha measures the amount that position in enVVeno Medical Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Payables Turnover | 1.15 | 1.21 | Days Of Inventory On Hand | 36.85 | 32.76 |
EnVVeno Medical Upcoming Company Events
As portrayed in its financial statements, the presentation of EnVVeno Medical's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, EnVVeno Medical's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of EnVVeno Medical's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of EnVVeno Medical. Please utilize our Beneish M Score to check the likelihood of EnVVeno Medical's management manipulating its earnings.
| 25th of January 2024 Upcoming Quarterly Report | View | |
| 6th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of January 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with EnVVeno Medical
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out EnVVeno Medical Backtesting, EnVVeno Medical Valuation, EnVVeno Medical Correlation, EnVVeno Medical Hype Analysis, EnVVeno Medical Volatility, EnVVeno Medical History and analyze EnVVeno Medical Performance. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
EnVVeno Medical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.